Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: A randomized, 26 weeks metformin-controlled, parallel-group study

Chinese Medical Journal

Volumn 125, Issue 15, 2012, Pages 2677-2681

  Yuan, Ge Heng ^a   Song, Wei Li ^b   Huang, You Yuan ^a   Guo, Xiao Hui ^a   Gao, Yan ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Exenatide; Metformin; Obesity; Type 2 diabetes

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; METFORMIN;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BODY MASS; BODY WEIGHT; BRASH; CONSTIPATION; CONTROLLED STUDY; DIABETIC OBESITY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOGLYCEMIA; IMMUNOASSAY; INFLUENZA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; NAUSEA; OBESITY; PEPTIDES; VENOMS; WEIGHT LOSS;

EID: 84865636331     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.15.006     Document Type: Article

References (18)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus-Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
2. Ferrannini E. The stunned beta cell: a brief history. Cell Metab 2010; 11: 349-352.
3. Turner RC, Cull CA, Stratton IM, Manley SE, Kohner EM, Matthews DR, et al. UK Prospective Diabetes Study 16-overview of 6 years therapy of type-II diabetes: A progressive disease. Diabetes 1995; 44: 1269-1258.
4. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009; 122: S3-S10.
5. Nauck MA, Niedereichholz U, Ettler R. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273(5 Pt 1): E981-E988.
6. Vilsboll T, Toft-Nielsen MB, Krarup T. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 2000; 23: 807-812.
7. Heine RJ, Diamant M, Mbanya JC, Nathan DM. Management of hyperglycaemia in type 2 diabetes. BMJ 2006; 333: 1200-1204.
8. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124: S3-S18.
9. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
10. Nolan JJ. Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia 2010; 53: 1247-1249.
11. Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 2011; 60: 1-23.
12. Moretto TJ, Milton DR, Ridge TD, Okerson T, Wolka AM, Brodows RG. Efficacy and tolerability of exenatide monotherapy over weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo controlled, parallel-group study. Clin Ther 2008; 30: 1448-1460.
13. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
14. Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Tecknol Tker 2007; 9: 317-326.
15. DeFronzo IRA, Ratner RE, Han J. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
16. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, et al. Effects of exenatide (exendin-4) on glycemic control over 52 weeks in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-5997.
17. Kendall DM, Riddle MC, Rosenstock J. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
18. Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial. Ann lntem Med 2007; 146: 477-485.